Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Stock Has Average Price Target of $6.00

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) have been given an average rating of “Hold” by the five brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $6.00.

Several research analysts have weighed in on CTXR shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Monday, September 21st. Citigroup reissued a “buy” rating on shares of Citius Pharmaceuticals in a report on Wednesday, August 19th. Finally, HC Wainwright reissued a “buy” rating on shares of Citius Pharmaceuticals in a research report on Wednesday, August 19th.

Institutional Trading of Citius Pharmaceuticals

An institutional investor recently bought a new stake in Citius Pharmaceuticals stock. BlackRock Inc. acquired a new stake in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 69,850 shares of the company’s stock, valued at approximately $42,000. BlackRock Inc. owned 0.25% of Citius Pharmaceuticals as of its most recent SEC filing. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Price Performance

Citius Pharmaceuticals stock opened at $0.55 on Monday. The company has a market capitalization of $14.96 million, a price-to-earnings ratio of -0.33 and a beta of 1.05. The company has a current ratio of 0.84, a quick ratio of 0.40 and a debt-to-equity ratio of 0.08. Citius Pharmaceuticals has a 12 month low of $0.37 and a 12 month high of $1.54. The stock’s 50 day moving average is $0.53 and its 200-day moving average is $0.65.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.02. Equities research analysts expect that Citius Pharmaceuticals will post -2.03 EPS for the current year.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for critical care, oncology and other areas with significant unmet medical needs. The company is headquartered in Cranford, New Jersey, and has primarily focused its development and commercialization activities on the U.S. healthcare market.

Citius’ lead product candidate has been Mino-Lok, an antibiotic lock solution designed to help salvage infected central venous catheters by treating catheter-related bloodstream infections while allowing the catheter to remain in place.